ChanLingGao alleviates intestinal mucosal barrier damage and suppresses the onset and progression of Colorectal cancer in AOM/DSS murine model
This study demonstrates that CLG can inhibit CRC tumor growth by regulating the gut microbiota structure, reducing intestinal inflammation, improving intestinal mucosal barrier function, and inhibiting the complex process of cancer cell proliferation. This provides new clinical insights into the "membrane-oriented" treatment of CRC with CLG.
Authors
- Kai Sun (ORCID: https://orcid.org/0000-0002-4784-0782)
- J. Liu (ORCID: https://orcid.org/0000-0001-6726-3268)
- Fei-Qing Wang
- Bing Yang (ORCID: https://orcid.org/0000-0002-0408-4518)
- Tingting Tian (ORCID: https://orcid.org/0000-0001-8767-091X)
- Yang Liu (ORCID: https://orcid.org/0000-0001-5553-3646)
- Xiaoyi Wang (ORCID: https://orcid.org/0000-0002-4656-8449)
- Guo Chen (ORCID: https://orcid.org/0009-0008-0369-1739)
- Dongxin Tang
- Jing‐Yan Han (ORCID: https://orcid.org/0000-0002-2286-8076)
Institutions
- Peking University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1016/j.intimp.2024.113193
- Citations
- 11
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.30